Company: CSCIF
Filing Date: 2025-04-09
Form Type: 20-F
Source: 0001641172-25-003456
Chunk: 69

Company: COSCIENS Biopharma Inc.
Filing Date: 2025-04-09
Form: 20-F
Item: Item 5
Chunk 69
---
) Technology. EFP is mostly used to produce liquid formulations while PGX is used for powder formulations.
PGX is a patented, unique and disruptive technology with several key advantages over conventional drying and purification technologies
that can be used to process biopolymers into high-value and novel biocomposites. In a single step and using green solvents, it has the
ability to generate purified highly porous polymer composites such as aerogels which cannot be made using conventional drying technologies.
In 2023, the Company commenced a collaboration with Austria-based NATEX Prozesstechnologie GesmbH to accelerate the scale-up of PGX Technology
at both its Edmonton facility and at the Natex Termitz facility. The project has been completed at the end of 2024 in Edmonton while
it is expected to be completed in Q2, 2025 in Austria.

  48  

Given
the well-known properties of oat beta glucan and avenanthramides as cholesterol reducer and anti-inflammation respectively, we are actively
developing our oat-based pipeline products to address unmet needs within the nutraceuticals markets, with a strategic focus on:

Oat
Beta Glucan - Chewable for cholesterol reduction

Leveraging
approved claims for the use of oat beta glucan as a proven cholesterol reduction ingredient in Canada, the United States of America and
the European Union, the Company has formulated a healthy edible product capable of delivering the appropriate dose of oat beta glucan
to meet all regulatory and health requirements. Commercial manufacturing samples have been produced, proving manufacturability of a healthy
and delicious edible product containing the high levels of oat beta glucan required to provide a scientifically proven cholesterol reduction
in humans. The Company intends to bring this product to the wellness and functional food market B2C via various e-commerce platforms
during the first 6 months of 2025.

Avenanthramides
 - nutraceutical-chewable formulation to reduce inflammation

In
addition to cosmetic applications, avenanthramides, when taken orally, could treat inflammation-based conditions such as exercise induced
inflammation, joint inflammation as well as inflammation at the gastro-intestinal and cardiovascular levels.

Through
the use of a unique chromatography purification technology, the Company has successfully developed a highly purified and well characterized
pharmaceutical grade powder formulation with the goal that such active pharmaceutical ingredient (API) could be offered as both nutraceutical
and pharmaceutical formulations.

The
Company’s